UNLABELLED: ACTH-secreting tumors represent 10% of functioning pituitary adenomas, and most of them are microadenomas. It is generally accepted that only half of these tumors are correctly identified with current magnetic resonance imaging (MRI) techniques. The objective of the paper is to report a method for detecting suspected ACTH-secreting pituitary tumors undetectable by conventional dynamic MRI using dynamic 3-Tesla MRI (3T MRI) and half-dose gadopentetate dimeglumine (0.05 mmol/Kg). Eight patients were included (5 men and 3 women) with a mean age of 29.12 years. Each of them had a confirmed diagnosis of Cushing disease and a negative dynamic MRI for microadenoma using full-dose gadopentetate dimeglumine. A second MRI was then performed using only half the usual dose of contrast material. Images from the second MRI where compared with the first study. Microadenomas were detected in 100% of the patients using a half dose of the contrast. All were recognized on the basis of the presence of a hypointense nodular lesion surrounded by normal contrast-enhanced tissue. Six patients were submitted to surgery, and the results were confirmed by immunohistochemistry in all of them. The remaining subject had a sinus sample catheterization coincident with the MRI results. CONCLUSION: A half dose of dynamic resonance imaging contrast material increases the sensitivity of MRI detection of ACTH-secreting pituitary tumors.
UNLABELLED: ACTH-secreting tumors represent 10% of functioning pituitary adenomas, and most of them are microadenomas. It is generally accepted that only half of these tumors are correctly identified with current magnetic resonance imaging (MRI) techniques. The objective of the paper is to report a method for detecting suspected ACTH-secreting pituitary tumors undetectable by conventional dynamic MRI using dynamic 3-Tesla MRI (3T MRI) and half-dose gadopentetate dimeglumine (0.05 mmol/Kg). Eight patients were included (5 men and 3 women) with a mean age of 29.12 years. Each of them had a confirmed diagnosis of Cushing disease and a negative dynamic MRI for microadenoma using full-dose gadopentetate dimeglumine. A second MRI was then performed using only half the usual dose of contrast material. Images from the second MRI where compared with the first study. Microadenomas were detected in 100% of the patients using a half dose of the contrast. All were recognized on the basis of the presence of a hypointense nodular lesion surrounded by normal contrast-enhanced tissue. Six patients were submitted to surgery, and the results were confirmed by immunohistochemistry in all of them. The remaining subject had a sinus sample catheterization coincident with the MRI results. CONCLUSION: A half dose of dynamic resonance imaging contrast material increases the sensitivity of MRI detection of ACTH-secreting pituitary tumors.
Authors: Dalia Batista; Nickolas A Courkoutsakis; Edward H Oldfield; Kurt J Griffin; Meg Keil; Nickolas J Patronas; Constantine A Stratakis Journal: J Clin Endocrinol Metab Date: 2005-06-07 Impact factor: 5.958
Authors: Carsten Krautmacher; Winfried A Willinek; Henriette J Tschampa; Mark Born; Frank Träber; Jürgen Gieseke; Hans J Textor; Hans H Schild; Christiane K Kuhl Journal: Radiology Date: 2005-10-19 Impact factor: 11.105
Authors: P C Davis; K A Gokhale; G J Joseph; S B Peterman; D A Adams; G T Tindall; P A Hudgins; J C Hoffman Journal: Radiology Date: 1991-09 Impact factor: 11.105
Authors: Lukas Andereggen; Gerhard Schroth; Jan Gralla; Rolf Seiler; Luigi Mariani; Jürgen Beck; Hans-Rudolf Widmer; Robert H Andres; Emanuel Christ; Christoph Ozdoba Journal: Neuroradiology Date: 2011-08-02 Impact factor: 2.804
Authors: M Kinoshita; H Tanaka; H Arita; Y Goto; S Oshino; Y Watanabe; T Yoshimine; Y Saitoh Journal: AJNR Am J Neuroradiol Date: 2015-01-15 Impact factor: 3.825
Authors: Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller Journal: Lancet Diabetes Endocrinol Date: 2021-10-20 Impact factor: 32.069
Authors: Prashant Chittiboina; S Lalith Talagala; Hellmut Merkle; Joelle E Sarlls; Blake K Montgomery; Martin G Piazza; Gretchen Scott; Abhik Ray-Chaudhury; Russell R Lonser; Edward H Oldfield; Alan P Koretsky; John A Butman Journal: J Neurosurg Date: 2016-03-18 Impact factor: 5.115